Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 18, 2009CirculationOpen Access

Recombinant α-galactosidase A therapy was evaluated for the amelioration of cardiovascular manifestations in patients with Fabry disease, though no quantitative results were reported in the abstract.

View Full Paper
Ask AI
Bookmark
Share

Key result

Recombinant α-galactosidase A therapy was evaluated for the amelioration of cardiovascular manifestations in patients with Fabry disease, though no quantitative results were reported in the abstract.

Authors

LBLouis Maximilian Buja

Discussion

Loading...

Member takes

Overview

Persistent CV risk persists in Fabry despite therapy; observational data leave optimal prevention strategies open for prospective trials.

PICO

P
Population
Fabry disease
I
Intervention / Comparator
Recombinant α-Galactosidase A Therapy

Cite This Study

Louis Maximilian Buja (2009) conducted a review in Fabry disease. Recombinant α-Galactosidase A Therapy was evaluated. Recombinant α-galactosidase A therapy was evaluated for the amelioration of cardiovascular manifestations in patients with Fabry disease, though no quantitative results were reported in the abstract.

synapsesocial.com/papers/6ab8d8f328472e268eb08688https://doi.org/10.1161/circulationaha.109.861534
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiac involvement in Fabry disease2002 · 40 citations
  2. 2A Rare Case of Fabry’s Disease-Induced Cardiomyopathy: A Case Report and Review of the Literature2024 · 1 citations
  3. 3Gastrointestinal involvement in fabry disease2024 · 3 citations
  4. 4Cardiac manifestations of Fabry disease2025
  5. 5A review on comparing diagnostic methods and current and emerging treatment options for long term management of Fabry disease.2026